Navigation Links
Scientists uncover strategy able to dramatically reduce chemotherapy's side effects
Date:8/14/2012

Researchers in Leuven (VIB/KU Leuven) have confirmed their hypothesis that normalizing blood vessels by blocking oxygen sensor PHD2 would make chemotherapy more effective. They also demonstrated for the first time that this strategy would reduce the harmful side effects of chemotherapy on healthy organs.

Limited success of chemotherapy

The effectiveness of chemotherapy is first and foremost limited by the difficulties of delivering the anticancer drugs to the actual tumor. Tumors are characterized by abnormally shaped blood vessels they are irregular in shape, have weak textures and easily tear. These leaking blood vessels prevent anticancer drugs from reaching tumor cells while promoting metastasis. Secondly, chemotherapy can have seriously harmful effects on healthy organs, leading even to heart and kidney failure.

Oxygen sensor (PHD2)

Earlier research at Max Mazzone's lab had already shown that reduced activity of the oxygen sensor PHD2 under hypoxic conditions resulted in a more streamlined vasculature. In this new study, and using mouse models, Rodrigo Leite de Oliveira, Sofie Deschoemaker and Max Mazzone prove their earlier hypothesis that streamlining blood flow by inhibiting PHD2 can render cancer treatments more effective. Firstly, the better formed blood vessels ensure that the anticancer drugs are distributed throughout the tumor, thus increasing their impact. They also allow for smaller doses a significant advantage when administering toxic drugs. The researchers further proved that inhibiting PHD2 results in the production of anti-oxidant enzymes able to neutralize the harmful side effects of chemotherapy.

A first step toward increasing the effectiveness of chemotherapy

The study is promising: chemotherapy combined with specific PHD2 inhibitors would make chemotherapy more effective while reducing the harmful side effects that place such a heavy burden on patients. Unfortunately, there are no specific PHD2 inhibitors available right now, so we have a long way to go before patients will be able to benefit from this discovery.


'/>"/>

Contact: Max Mazzone
Massimiliano.mazzone@vib-kuleuven.be
32-485-404-904
VIB (the Flanders Institute for Biotechnology)
Source:Eurekalert

Related biology news :

1. Stanford scientists develop gene therapy approach to grow blood vessels in ischemic limbs
2. Queens scientists seek vaccine for Pseudomonas infection
3. Scientists produce eye structures from human blood-derived stem cells
4. American Society of Plant Biologists honors early career women scientists
5. Brandeis scientists win prestigious prize for circadian rhythms research
6. Scientists discover new method of proton transfer
7. Salk scientists open new window into how cancers override cellular growth controls
8. WileyChina.com - Now Featuring Bespoke Pages for China’s Life Scientists
9. Scientists win $2 million to study new pathway in development and maintenance of lymphoma
10. UGA scientists reveal genetic mutation depicted in van Goghs sunflower paintings
11. Genetic mutation depicted in van Goghs sunflower paintings revealed by scientists
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/15/2016)... Research and Markets has announced ... 2016-2020,"  report to their offering.  , ... global gait biometrics market is expected to grow ... 2016-2020. Gait analysis generates multiple variables ... to compute factors that are not or cannot ...
(Date:4/13/2016)...  IMPOWER physicians supporting Medicaid patients in ... standard in telehealth thanks to a new partnership with ... IMPOWER patients can routinely track key health measurements, such ... and, when they opt in, share them with IMPOWER ... local retail location at no cost. By leveraging this ...
(Date:3/31/2016)... , March 31, 2016  Genomics firm Nabsys has ... CEO, Barrett Bready , M.D., who returned to ... the original technical leadership team, including Chief Technology Officer, ... Product Development, Steve Nurnberg and Vice President of Software ... the company. Dr. Bready served as CEO ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... ... , ... Supplyframe, the Industry Network for electronics hardware design ... Located in Pasadena, Calif., the Design Lab’s mission is to bring together inventors ... and brought to market. , The Design Lab is Supplyframe’s physical representation of ...
(Date:6/23/2016)... 23, 2016 Apellis Pharmaceuticals, Inc. today ... trials of its complement C3 inhibitor, APL-2. The ... ascending dose studies designed to assess the safety, ... injection in healthy adult volunteers. Forty ... a single dose (ranging from 45 to 1,440mg) ...
(Date:6/23/2016)... -- On Wednesday, June 22, 2016, the NASDAQ ... Dow Jones Industrial Average edged 0.27% lower to finish at ... Stock-Callers.com has initiated coverage on the following equities: Infinity Pharmaceuticals ... NKTR ), Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ ... Learn more about these stocks by accessing their free trade ...
(Date:6/23/2016)... ... 2016 , ... Velocity Products, a division of Morris Group, ... exclusively for Okuma CNC machining centers at The International Manufacturing Technology Show, IMTS, ... companies with expertise in toolholding, cutting tools, machining dynamics and distribution, Velocity SMART ...
Breaking Biology Technology: